Phase 1 Colorectal Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have been diagnosed with locally advanced or metastatic colorectal cancer (cancer that has spread beyond the colon or rectum), confirmed by a tissue sample, and whose cancer has stopped responding to or who could not tolerate standard treatments — and, where applicable, people with a specific tumor type called MSI-H who have already received a type of treatment called an immune checkpoint inhibitor, unless it was not suitable for them.
- People whose general health and ability to carry out daily activities meets a specific level set by doctors (known as ECOG performance status of 0 or 1, meaning fully active or able to carry out light activity).
- People whose blood counts, liver function, and kidney function are within the ranges required by the trial.
- Other criteria defined in the trial protocol may also apply (confirm with trial site).
Who may not be able to join:
- People who have had another type of cancer within the past 3 years, with some exceptions such as certain skin cancers, early-stage cervical changes, benign prostate conditions, or cancers considered fully cured with very low chance of returning (confirm with trial site).
- People with cancer that has spread to the brain, unless those brain metastases have already been treated, have been stable for at least 4 weeks, and are not currently causing neurological symptoms related to the cancer itself.
- People experiencing diarrhea (loose or liquid stools) or bowel blockage rated as moderate or severe.
- People with active ongoing inflammatory bowel conditions such as ulcerative colitis, Crohn's disease, intestinal perforation, or a bowel obstruction.
- People with certain serious heart conditions — including unstable chest pain, a recent heart attack, moderate-to-severe heart failure, or a heart procedure in the past 180 days — or people with a specific abnormality on a heart tracing (ECG) measurement above a set threshold.
- People who have had a stroke within the past 6 months.
- Other criteria defined in the trial protocol may also apply (confirm with trial site).
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Medical Responsible, EMD Serono Research & Development Institute, Inc.
Phone: 888-275-7376
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Part 1: Number of Participants with Dose Limiting Toxicities (DLTs) and Adverse Events (AEs); Part 1: Recommended Dose Expansion (RDE) of M9140; Parts 2B, 2C and 2D: Number of Participants with Dose Limiting Toxicities (DLTs) and Adverse Events (AEs); Part 2A: Number of Participants with Adverse Events (AEs); Part 2A: Objective Response (OR) According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) as Assessed by Investigators; Part 2A: Duration of Response (DoR) According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) as Assessed by Investi...
Can't join this trial?
Data last synced from ClinicalTrials.gov: 14 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.